The emergence of COVID-19 has substantially disrupted delivery of cancer care, with postponements and cancellations of surgeries, as well as delays in systemic and radiotherapies. For patients with slow-growing tumors, these delays may be safe, but for others, waiting to start treatment can have a negative impact on outcomes. The benefits and risks of immediate […]

Atlanta, GA, and Nashville, TN – February 18, 2021 — Aptitude Health, a global healthcare and oncology solutions leader, today announced that it has entered into a strategic partnership with OneOncology, the national partnership of independent community oncologists driving the future of cancer care in the U.S. The first collaboration will incorporate Aptitude Health’s proprietary […]

Measurable (formerly minimal) residual disease, or MRD, refers to low levels of leukemia that cannot be detected by morphologic assessment alone. While not a new concept in the management of patients with leukemias, MRD testing in the management of acute myeloid leukemia (AML) has recently gained increased attention among disease-state experts. In a large-cohort meta-analysis […]

As 2019 drew to a close, pharma organizations looked forward to a blockbuster year. Analysts weighed the numbers and made predictions for 2020; but COVID-19 shattered many of their predictions. The global pandemic has led to one of the most tumultuous years in recent memory. There’s no doubt that the pandemic created upheaval in pharma […]

In 2020, COVID-19 had only a minimal effect on drug approvals, which were considerably higher in comparison with 2019. The US Food and Drug Administration (FDA) approved more than 50 new medicines and therapeutic biologics in 2020, more than a third of which were oncology/hematology treatments. Similarly, the European Medicines Agency’s Committee for Medicinal Products […]